Abstract

BACKGROUNDA current challenge in bioprocessing is the ability to analyse critical quality attributes such as aggregation without prior purification. This study evaluated the use of fluorescent dyes (Bis‐ANS, SYPRO Orange, Thioflavin T and ProteoStat) to characterise mAb aggregates in Chinese hamster ovary clarified cultures.RESULTSThe null and mAb culture supernatants showed an increase in fluorescence intensity over the duration of the culture. The null cultures on day 14 saw a rapid increase in fluorescence intensity; day 10 to day 14, Bis‐ANS and Thioflavin T had average increases of 21% and 48%, respectively, whereas ProteoStat and SYPRO Orange showed an average increase of 60%. Higher fluorescence intensity on day 14 with the null cultures, also correlated with loss of viability.CONCLUSIONFluorescent dyes are not a specific indicator of mAb aggregation, but rather an indicator of overall protein aggregation or high molecular weight species. SYPRO Orange was more sensitive at detecting very large molecular weight species and ProteoStat seemed better suited to smaller aggregates. Although the assay cannot be used to measure mAb aggregates in cell culture, it could be used to aid cell line selection in maximising viabilities and minimising the amount of aggregates. © 2017 The Authors. Journal of Chemical Technology & Biotechnology published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

Highlights

  • The development process of monoclonal antibodies is highly regulated due to the 108 possible variants.[1]

  • We investigated the suitability of extrinsic dyes to detect less than 10% monoclonal antibodies (mAbs) aggregates in Chinese hamster ovary (CHO) cell culture supernatants at varying culture time points up to day 14

  • Potential of the four dyes for mAb aggregate detection in CHO cell cultures, first the dyes were verified in a purified system with thermally stressed mAb aggregates

Read more

Summary

Introduction

The development process of monoclonal antibodies (mAbs) is highly regulated due to the 108 possible variants.[1]. To ensure high quality drugs are consistently produced, biopharmaceutical companies are becoming more risk adverse and moving towards characterising product quality earlier in development. QbD starts with identifying critical quality attributes (CQAs) which can be categorised as product or process related. Product related impurities are molecular variants of the product such as aggregates, incorrect glycosylation, charge variants, oxidation and fragmentation. Process related impurities are a result of the process environment introducing additional components to the product e.g. DNA, host cell proteins (HCP) and viruses. For mAbs, companies typically aim to have

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call